<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105376</url>
  </required_header>
  <id_info>
    <org_study_id>TNS_depression</org_study_id>
    <nct_id>NCT02105376</nct_id>
  </id_info>
  <brief_title>TNS for Major Depressive Disorder: a Phase II Randomized Controlled Trial</brief_title>
  <official_title>The Effects of Trigeminal Nerve Stimulation (TNS) for the Treatment of Major Depressive Disorder: a Phase II, Randomized, Sham Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santa Casa Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculdade de Ciências Médicas da Santa Casa de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Santa Casa Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomized, sham controlled, clinical trial. This clinical trial has as
      primary objective to evaluate the effect of the Trigeminal Nerve Stimulation (TNS) on
      depressive symptoms measured by the Hamilton Depressive Rating Scale version 17 items
      (HDRS-17) in patients with moderate / severe depressive episode.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depressive Rating Scale version 17 items (HDRS-17)</measure>
    <time_frame>Change from baseline in depressive symptoms at 2 weeks</time_frame>
    <description>This clinical trial has as primary objective to evaluate the effect of the Trigeminal Nerve Stimulation (TNS) on depressive symptoms measured by the Hamilton Depressive Rating Scale version 17 items (HDRS-17) in patients with moderate / severe depressive episode.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MOCA)</measure>
    <time_frame>Change from baseline in cognitive functioning at 2 weeks</time_frame>
    <description>We also use the questionnaire Montreal Cognitive Assessment (MOCA) for assessment of cognitive function, considering the level of consciousness and global functioning in order to compare your score with estimates made by other instruments. It will also serve to assess possible cognitive damage and whether there are improvements in some specific cognitive functions with treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>Trigeminal Nerve Stimulation (TNS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNS active group
TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TNS sham
The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trigeminal Nerve Stimulation (TNS)</intervention_name>
    <description>Trigeminal Nerve Stimulation (TNS)</description>
    <arm_group_label>Trigeminal Nerve Stimulation (TNS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients between 18 and 69 years

          2. patients with a diagnosis of depression according to the SCID

          3. score greater than or equal to 18 on the Hamilton Rating Scale 17-item version
             (equivalent to moderate or severe depressive episode)

          4. agreement to participate in the study as recommended in the IC.

        Exclusion Criteria:

          1. patients with psychiatric indication for hospitalization

          2. patients with psychiatric comorbidity

          3. patients with a diagnosis of personality disorder

          4. presence of severe neurological or medical diseases such as neoplasms in activity,
             neurodegenerative diseases and chronic diseases uncompensated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quirino Cordeiro, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Santa Casa Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Shiozawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Casa Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Shiozawa, MD</last_name>
    <phone>55 11 34662100</phone>
    <email>pedroshiozawa@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Atencao Integrada à Saúde Mental</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04017030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Shiozawa, MD</last_name>
      <phone>55 11 34662100</phone>
      <email>pedroshiozawa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Shiozawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quirino Cordeiro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Cook IA, Schrader LM, Degiorgio CM, Miller PR, Maremont ER, Leuchter AF. Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy Behav. 2013 Aug;28(2):221-6. doi: 10.1016/j.yebeh.2013.05.008. Epub 2013 Jun 14.</citation>
    <PMID>23773978</PMID>
  </reference>
  <reference>
    <citation>DeGiorgio CM, Fanselow EE, Schrader LM, Cook IA. Trigeminal nerve stimulation: seminal animal and human studies for epilepsy and depression. Neurosurg Clin N Am. 2011 Oct;22(4):449-56, v. doi: 10.1016/j.nec.2011.07.001. Review.</citation>
    <PMID>21939843</PMID>
  </reference>
  <reference>
    <citation>Schrader LM, Cook IA, Miller PR, Maremont ER, DeGiorgio CM. Trigeminal nerve stimulation in major depressive disorder: first proof of concept in an open pilot trial. Epilepsy Behav. 2011 Nov;22(3):475-8. doi: 10.1016/j.yebeh.2011.06.026. Epub 2011 Aug 4.</citation>
    <PMID>21820361</PMID>
  </reference>
  <reference>
    <citation>Shiozawa P, Cordeiro Q, Fregni F, Brunoni AR. Is sertraline plus transcranial direct current stimulation the future of effective depression treatment? J Comp Eff Res. 2013 May;2(3):213-5. doi: 10.2217/cer.13.28.</citation>
    <PMID>24236617</PMID>
  </reference>
  <reference>
    <citation>Riva-Posse P, Hermida AP, McDonald WM. The role of electroconvulsive and neuromodulation therapies in the treatment of geriatric depression. Psychiatr Clin North Am. 2013 Dec;36(4):607-30. doi: 10.1016/j.psc.2013.08.007. Epub 2013 Oct 6. Review.</citation>
    <PMID>24229660</PMID>
  </reference>
  <reference>
    <citation>Vuilleumier P, Sander D, Baertschi B. Changing the brain, changing the society: clinical and ethical implications of neuromodulation techniques in neurology and psychiatry. Brain Topogr. 2014 Jan;27(1):1-3. doi: 10.1007/s10548-013-0325-7. Epub 2013 Oct 25.</citation>
    <PMID>24158724</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <last_update_submitted>May 3, 2015</last_update_submitted>
  <last_update_submitted_qc>May 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Ciências Médicas da Santa Casa de São Paulo</investigator_affiliation>
    <investigator_full_name>Pedro Shiozawa</investigator_full_name>
    <investigator_title>Pedro Shiozawa, Coordinator, Laboratory of Clinical Neuromodulation, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>cranial nerve stimulation</keyword>
  <keyword>trigeminal stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

